Tuesday, November 29, 2011

Strategic Analysis

!±8± Strategic Analysis

What is The BCG Growth-Share Matrix? What are the main aspects of The BCG Growth-Share Matrix? How to develop Good BCG Growth-Share Matrix of a company? Where to find information for The BCG Growth-Share Matrix?

INTRODUCTION
No strategic management or marketing text appears to be complete without the inclusion of the Boston Consulting Group (BCG) growth-share matrix. When used effectively, this model provides guidance for resource allocation. And despite its inherent weaknesses, is probably one of the most widely used management instrument as far as portfolio management is concern. For instant, each SBU (strategic business unit) of large companies such as General Electric, Siemens, and Centrica require different strategies to compete effectively and efficiently. It is not a question of one strategy fits all SBUs since the likelihood for each of them experiencing the same market growth rate, industry-threats and leverage is very slim. This is where the BCG model comes into play as a management analytical tool. The ensuing examines the underpinnings of the model, for what it is used, how to use it and why it is used.

WHAT IS THE BCG GROWTH-SHARE MATRIX?
To begin with, BCG is the acronym for Boston Consulting Group-a general management consulting firm highly respected in business strategy consulting. BCG Growth-Share Matrix (see figure 1) happens to be one of many of BCG's strategic concepts the organisation developed in the late 1970s, and is being taught at leading business schools and executive education programmes around the world.

It is a management tool that serves four distinct purposes (McDonald 2003; Kotler 2003; Cipher 2006): it can be used to classify product portfolio in four business types based on four graphic labels including Stars, Cash Cows, Question Marks and Dogs; it can be used to determine what priorities should be given in the product portfolio of a company; to classify an organisation's product portfolio according to their cash usage and generation; and offers management available strategies to tackle various product lines. Consider companies like Apple Computer, General Electric, Unilever, Siemens, Centrica and many more, engaging in diversified product lines. The BCG model therefore becomes an invaluable analytical tool to evaluate an organisation's diversified product lines as later seen in the ensuing sections.

WHAT ARE THE MAIN ASPECTS OF THE BCG GROWTH-SHARE MATRIX?
The BCG Growth-Share Matrix is based on two dimensional variables: relative market share and market growth. They often are pointers to healthiness of a business (Kotler 2003; McDonald 2003). In other words, products with greater market share or within a fast growing market are expected to wield relatively greater profit margins. The reverse is also true. Let's look at the following components of the model:
Fig. 1: Source: 12manage.com 2006

Relative Market Share
According to the proponents of the BCG (Herndemson 1972), It captures the relative market share of a business unit or product. But that is not all! It allows the analysed business unit be pitted against its competitors. As earlier emphasized above, this is due to the sometime correlation between relative market share and the product's cash generation. This phenomenon is often likened to the experience curve paradigm that when an organisation enjoys lower costs, improved efficiency from conducting business operations overtime. The basic tenet of this postulation is that the more an organisation performs a task often; it tends to develop new ways in performing those tasks better which results in lower operating cost (Cipher 2006). What that suggests is that the experience curve effect requires that market share is increased to be able to drive down costs in the long run and at the same time a company with a dominant market share will inevitably have a cost advantage over competitor companies because they have the greater share of the market. Hence, market share is correlated with experience.

A case in point is Apple Computer's flagship product called the iPod, which occupies a dominant 73% share the portable music player market (Cantrell 2006). Analysts believe it is the impetus for Apple's financial rebirth 40% of Apple's sales is attributed to the iPod product line (Cantrell 2006). Similarly, Dell's PC line shares the same market dominance theory as the iPod. The PC manufacture giant occupies a worldwide market share of 18.1%, which is commensurate to its large market revenue above its competitors (see figure 2).
Figure 2: Source: Reuters 2006

Market Growth
Market growth axis, correlates with the product life cycle paradigm, and predicates the cash requirement a product needs relative to the growth of that market. A fast growing market is generally considered attractive, and pulls a lot of organisation's resources in an effort to increase gains. A case in point is the technological market widely consider by experts as a fast growing market, and tends to attract a lot of competition. Therefore, a product life cycle and its associated market play a key role in decision-making.

Cash Cows
These products are said to have high profitability, and require low investment for the fact that they are market leaders in a low-growth market. This viewpoint is captured by the founders themselves thus:

The cash cows fund their own growth. They pay the corporate dividend. They pay the corporate overhead. They pay the corporate interest charges. They supply the funds for R&D. They supply the investment resource for other products. They justify the debt capacity for the whole company. Protect them (Henderson 1976).

According to experts (Drummond & Ensor 2004; Kotler 2003; McDonald 2003), surplus cash from cash cow products should be channelled into Stars and Questions in order to create the future Cash Cows.

Stars
Stars are leaders in high growth markets. They tend to/should generate large amounts of cash but also use a lot of cash because of growth market conditions. For example, Apple Computer has a large share in the rapidly growing market for portable digital music players (Cantrell 2006).

Question Marks
Question Marks have not achieved a dominant market position, and hence do not generate much cash. They tend to use a lot of cash because of growth market conditions. Consider Hewlett-Packard's small share of the digital camera market, behind industry leader Canon's 21% (Canon 2006). However, this is a rapidly growing market.

Dogs
Dogs often have little future and are big cash drainers on the company as they generate very little cash by virtue of their low market share in a highly low growth market.
Consider Pfizer's Inspra (Gibson 2006):

"Pfizer launched this drug in Q4 2003 and continues to pump money into this problem child, despite anaemic sales of roughly million in the .7 billion heart-failure market dominated by Toprol-XL (metoprolol). It was thought to gain market share and become a star, and eventually a cash cow when the market growth slowed. But, according to industry's experts, Inspra is likely to remain a dog, despite any amount of promotion, given its perceived safety issues and a cheaper, more effective spironolactone in the same Pfizer portfolio. Because Pfizer invested heavily in promotion early on with Inspra, the drug's earnings potential and positive cash flow is elusive at best. A portfolio analysis of Pfizer's cardiovascular franchise would suggest redeploying promotional spend on Inspra to up-and-coming stars like Caduet (amlodipine/atorvastatin) or torcetrapib to ensure those drugs reach their sales potential."

HOW TO DEVELOP GOOD BCG GROWTH-SHARE MATRIX OF A COMPANY?
SBUs or products are represented on the model by circles and fall into one of the four cells of the matrix already described above. Mathematically, the mid-point of the axis on the scale of Low-High is represented by 1.0 (Drummond & Ensor 2004; Kotler 2003). At this point, the SBU's or product's market share equals that of its largest competitor's market share (Drummond & Ensor 2004; Kotler 2003). Next, calculate the relative market share and market growth for each SBU and product. Figure 3 depicts the formulas to calculate the relative market share and market growth.
Fig 3

Oftentimes, if you are versed with a particular industry and companies operating in it, you could draw up a BCG matrix for any company without necessarily computing figures for the relative market share and market growth. Figure 4 depicts a fairly accurate BCG growth-share matrix for Apple Computer developed in the spring of 2005 without the author calculating the relative market share and market growth.
Fig. 4 Source: Asong (2005)

Once the products or SBUs have been plotted, the planner then has to decide on the objective, strategy and budget for the business lines. Basically, at this juncture the organisations should strive to maintain a balanced portfolio. Cash generated from Cash Cows should flow into Stars and Question Marks in an effort to create future Cash Cows. Moreover, there are 4 major strategies that can be pursued at this stage as described in the ensuing section.

AVAILABLE STRATEGIES TO PURSUE

Build
The product or SBU's market share needs to be increased to strengthen its position. Short-term earnings and profits are deliberately forfeited because it is hoped that the long-term gains will be higher than this. This strategy is suited to Question Marks if they are to become stars.

Hold
The objective is to maintain the current share position and this strategy is often used for Cash Cows so that they continue to generate large amounts of cash.

Harvest
Here management tries to increase short-term cash flows as far as possible (e.g. price increase, cutting costs) even at the expense of the products or SBU's longer-term future. It is a strategy suited to weak Cash Cows or Cash Cows that are in a market with a limited future. Harvesting is also used for Question Marks where there is no possibility of turning them into Stars, and for Dogs.

Divest
The objective of this strategy is to rid the organisation of the products or SBUs that are a drain on profits and to utilize these resources elsewhere in the business where they will be of greater benefit. This strategy is typically used for Question Marks that will not become Stars and for Dogs.

WHERE TO FIND INFORMATION FOR THE BCG GROWTH-SHARE MATRIX?
Information for the BCG Growth-Share matrix is generated from multiple sources including company's annual reports, sec fillings and a host of specialised research organisations such as IDC, Hoover, Edgar, Forrester and many more. Armed with this information, developing a BCG growth-share matrix should pose less of a problem.

Limitations
The BCG model is criticised for having a number of limitations (Kotler 2003; McDonald 2003):

o There are other reasons other than relative market share and market growth that could influence the allocation of resources to a product or SBU: reasons such as the need for strong brand name and product positioning could compel resource allocation to an SBU or product (Drummond & Ensor 2004).

o What is more, the model rests on net cash consumption or generation as the fundamental portfolio balancing criterion. That is appropriate only in a capital constrained environment. In modern economies, with relatively frictionless capital flows, this is not the appropriate metric to apply - rather, risk-adjusted discounted cash flows should be used (ManyWorlds 2005).

o Also, the matrix assumes products/business units are independent of each other, and independent of assets outside of the business. In other words, there is no provision for synergy among products/business units. This is rarely realistic.

o The relationship between cash flow and market share may be weak due to a number of factors including (Cipher 2006): competitors may have access to lower cost materials unrelated to their relative share position; low market share producers may be on steeper experience curves due to superior production technology; and strategic factors other than relative market share may affect profit margins.

o In addition, the growth-share matrix is based on the assumption that high rates of growth use large cash resources and that maturity of the life cycle brings about the expected profit returns. This may be incorrect due to various reasons (Cipher 2006): capital intensity may be low and the business/product could be grown without major cash outlay; high entry barriers may exist so margins may be sustainable and big enough to produce a positive cash flow and a growth at the same time; and industry overcapacity and price competition may depress prices in maturity.

o Furthermore, market growth is not the only factor or necessarily the most important factor when assessing the attractiveness of a market. A fast growing market is not necessarily an attractive one. Growth markets attract new entrants and if capacity exceeds demand then the market may become a low margin one and therefore unattractive. A high growth market may lack size and stability.
Given the aforementioned weaknesses, the BCG Growth-Share matrix must be used with care; nonetheless, it is a best-known business portfolio evaluation model (Kotler 2003).

If you found this article useful please have a look at the other articles we have written: PEST analysis, Porter's 5 Forces analysis, Ansoff analysis, SWOT analysis, Porter's Generic Strategies, Scenario Planning, Value chain analysis.

REFERENCE
12Management (2006). BCG Matrix. www.12management.com [Accessed: September 23, 2006]
Asong, B. (2005). Case Study: Apple Computer Market Assessment and Product Launch Strategy. CLC-PHW: London, pp. 17-40.
BCG (2006). The Growth-Share Matrix. www.bcg.com [Accessed: September 20, 2006]
Canon (2006). InfoSource research puts Canon No.1 in the UK & Ireland. [Accessed: September 28, 2006]
Cantrell, A. (2006). Apple's Remarkable Comeback Story. [Accessed: September 28, 2006]
Drummond, G. & Ensor, J. (2004). Strategic Marketing: Planning & Control. 2nd Ed. Butterworth-Heinemann: MA, pp. 96-100.
Henderson, B. (1976). Anatomy of the Cash Cow. Accessed: September 21, 2006]
Lane, S. (2006). Overall Mac OS usage market share declining? [Accessed: September 28, 2006] http://www.appleinsider.com/article.php?id=2059
ManyWorlds (2005). Models and Concepts.[Accessed: September 24, 2006]
McDonald, M. (2003). Marketing Plans: How To Prepare Them, How To Use Them. MA: Butterworth-Heinemann, pp. 175-245.
MindTools (2006). The Boston Matrix. www.mindtools.com/pages/article/newTED_97.htm [Accessed: September 28, 2006]

BIBLIOGRAPHY
Cooper, R. G., Edgett, S. J., & Kleinschmidt, E.J. (2006). Portfolio Management. Working Paper No 12: The Product Development Institute.
Lee, C. K. (2004). Asia Zirconium Limited Valuation report. Prudential Tower: Standard & Poor's.
Vriens, D (2004). The Role of Information and Communication Technology in Competitive Intelligence. Idea Group Inc: University of Nijmegen.
Zolkiewski, J. & Turnbull, P. (undated). Relationship Portfolios-Past, Present & Future.


Strategic Analysis

Schwinn 460 Trainer Buy Recipe For Brie In Puff Pastry Buy Online

Sunday, November 27, 2011

Lipitor TV Commercial - Robert Jarvik

Thanks to www.pharmacytoyou.net Atorvastatin, sold by Pfizer under the trade name Lipitor, is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. Atorvastatin was first synthesized in 1985 by Bruce Roth while working at Parke-Davis Warner-Lambert Company (now Pfizer). With 2008 sales of US.4 billion, Lipitor was the top-selling branded pharmaceutical in the world. US patent protection is scheduled to expire in June 2011. However, Pfizer made an agreement with Ranbaxy Laboratories to delay the generic launch in the US until November 2011 Atorvastatin calcium tablets are marketed by Pfizer under the trade name Lipitor, in tablets (10, 20, 40 or 80 mg) for oral administration. Tablets are white, elliptical, and film coated. Pfizer also packages the drug in combination with other drugs, such as is the case with its Caduet. Pfizer recommends that patients do not break tablets in half to take half doses even when told it is okay to do this by their doctors, as in most cases, doctors are not aware of the company's recommendation stated on its website.

Single Cup Coffee Brewing Save

Friday, November 25, 2011

Blocking Ranbaxy's barrage of cholesterol drug, area is the logic?

The US Foods and Drugs Administration (USFDA) will be sued by the US pharmaceutical company Mylan Inc, for an injunction on the launch of Ranbaxy's cholesterol treatment drug Aricept, which is a generic version of Pfizer's Lipitor.

Golden Waffle Mix Clearance Sale Good Bargain Frye Boots Chicago Smith Wesson 3913 Buy Online

Tuesday, November 22, 2011

Buy Lipitor

Buy Lipitor online: buyrx24.com Use special coupon code "save10" and get 10% discount! Tags: buy cheap generic lipitor buy cheap no prescription lipitor online buy cheap order lipitor online buy discount lipitor buy generic lipitor drug buy generic lipitor online buy generic...

Bargain Sale Spun Floor Lamp Promotions Cat Garden Statues

Saturday, November 19, 2011

How Much Do Statins Lower Cholesterol? The Numbers For Statins Are Simply Amazing

!±8± How Much Do Statins Lower Cholesterol? The Numbers For Statins Are Simply Amazing

In this article titled how much does statins lower cholesterol we will talk a little about statins medications in general and then reveal some eye popping numbers as far as what you can expect in relation to results once you have been utilizing these very powerful cholesterol busting prescription medications for a week or two.

Did you know that the scientifically correct name for the statin category of drugs is HMG-CoA reductase inhibitors? I bet not! You are probably saying, who cares, just give me those stinking numbers so I can go on about my business. In due time, remember good things happen to those who wait.

The word inhibitors is a straightforward term whose meaning is to prevent an action with another action. Reductase, now that is another story. The ase is scientific lingo for enzyme. So we have reductase inhibitor which means a drug that interferes with an enzyme. The CoA stands for coenzyme A and finally HMG stands for beta-hydroxy-beta-methyl-glutaryl-CoA. Put it all together and we come up a prescription medication that reduces the activity of an enzyme needed to turn fats into lipoproteins and cholesterol.

Now let's move on to our topic of how much does statins lower cholesterol.

Statins currently are the darlings of the medical community. They put a beat down on cholesterol numbers unlike any past medication (with the possible exception of prescription niacin) with their primary benefit being that of reducing bad cholesterol or LDL. The numbers listed stating how much does statins lower cholesterol are based on maximum dosage consider safe by doctors and drug manufacturers.

*Crestor whose generic counterpart Rosuvastatin at a dosage of 40mg has been shown to reduce LDL cholesterol by 63% (no not a misprint).

*Lipitor whose generic counterpart Atorvastatin at a dosage of 89 mg has been shown to reduce LDL cholesterol by 60%.

*Zocor whose generic name is Simvastatin at a dosage of 80 mg has been shown to lower LDL cholesterol by 47%

*Lescol whose generic name is Fluvastatin at a dosage of 80 mg has been shown to lower LDL cholesterol by 36%.

*Mevacor whose generic name is Lovastatin at a dosage of 80mg has been show to lower LDL cholesterol by 42%.

*There are few others as well whose efficacy ranges from 40 to 50 percent they are Pravachol and the statin combo drugs Advicor and Caduet.

Pretty impressive set of numbers! But the very thing that makes statins amazing has also created a great deal of controversy about their safety. Some critics say that failure to supplement statin medications with large amounts of CoQ10 enzyme puts them at risk of cell and muscle death due to the possibility of cholesterol levels plummeting too low, ultimately causing cell death and possibly kidney failure. Nevertheless, most doctors believe these medications to be a safe and effective treatment for high cholesterol and will quickly tell you that their benefits far outweigh any potential risk.

Nevertheless, muscle pain, the risk of muscle death and ultimately kidney failure has driven many to natural cholesterol reducing remedies. If you believe that when asking how much does statins lower cholesterol, the answer is too much, a safe all natural solution for high cholesterol just might be a viable treatment option worth considering.


How Much Do Statins Lower Cholesterol? The Numbers For Statins Are Simply Amazing

Last Minute Sorel Glacier Boot Running Shoe Guide For Dummies Sale Discounted Hercules Dj Console Rmx Driver

Sunday, November 6, 2011

Buy Lipitor Online

Buy Lipitor brand and generic versions of atorvastatin for high cholesterol treatment from Canada Pharmacy Online. Lipitor dosages range from 10mg-80mg in tablet form.

Ionizers Water Clearance Sale


Twitter Facebook Flickr RSS



Fran�ais Deutsch Italiano Portugu�s
Espa�ol ??? ??? ?????







Sponsor Links